Tibia osteomyelitis secondary to BCG vaccination in an immunocompetent infant. Case report

Main Article Content

Javier Eugenio Dal Lago
Eduardo Jacobo Levy

Abstract

Abstract
Introduction: The Bacillus Calmette-Guérin (BCG) vaccine, used to prevent severe forms of tuberculosis (TB), is the most extensively used vaccine worldwide. Adverse events associated with BCG vaccination are rare, and most of them occur at the inoculation site. We present a tibia Osteomyelitis case secondary to BCG vaccination in an immunocompetent infant.
Conclusions: Bone involvement secondary to BCG vaccination in previously healthy patients is extremely rare. Healthcare providers must consider such settings in order to make the diagnosis and institute the appropriate treatment. Antituberculous drugs produced good therapeutic results with no need for surgical toilette.
 
 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
Dal Lago, J. E., & Levy, E. J. (2020). Tibia osteomyelitis secondary to BCG vaccination in an immunocompetent infant. Case report. Revista De La Asociación Argentina De Ortopedia Y Traumatología, 85(2), 157-166. https://doi.org/10.15417/issn.1852-7434.2020.85.2.965
Section
Case Presentations
Author Biographies

Javier Eugenio Dal Lago, Pediatrics Orthopedics Team, Hospital Británico de Buenos Aires (Buenos Aires, Argentina)

Pediatrics Orthopedics Team, Hospital Británico de Buenos Aires (Buenos Aires, Argentina)

Eduardo Jacobo Levy, Pediatrics Orthopedics Team, Hospital Británico de Buenos Aires (Buenos Aires, Argentina)

Pediatrics Orthopedics Team, Hospital Británico de Buenos Aires (Buenos Aires, Argentina)

References

1. World Health Organization. Global Tuberculosis Report 2015. Geneva: World Health Organization; 2015. https://apps.who.int/medicinedocs/documents/s22199en/s22199en.pdf

2. Ministerio de Salud de la República Argentina. Recomendaciones Nacionales de Vacunación Argentina 2012. http://www.msal.gob.ar/images/stories/bes/graficos/0000000451cnt-2013-06_recomendaciones-vacunacion-argentina-2012.pdf

3. Organización Mundial de la Salud. Hoja de información sobre las tasas observadas de reacciones a vacunas. Vacuna Bacilo de Calmette-Guérin (BCG); 2012. https://www.who.int/vaccine_safety/initiative/tools/BCG_Vaccine_rates_information_sheet_ES.pdf?ua=1

4. Ministerio de Salud de la República Argentina. Vacunación Segura: Vigilancia de eventos supuestamente atribuibles a la vacunación o inmunización (ESAVI); 2012. http://www.msal.gob.ar/images/stories/bes/graficos/0000000448cnt-2014-01_manual-vacunacion-segura-esavi.pdf

5. Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988;63(2):47-59. PMID: 3066422

6. Organización Mundial de la Salud. Documento de posición de la OMS sobre las vacunas BCG. Boletín Epidemiológico Semanal 2018;8(93):73-96. http://www9.who.int/immunization/policy/position_papers/pp_bgc_2018_ES.pdf

7. Lin WL, Chiu NC, Lee PH, Huang AS, Huang FY, Chi H, et al. Review management of Bacillus Calmette-Guérin osteomyelitis/osteitis in immunocompetent children-A systematic review. Vaccine 2015;33(36):4391-7. https://doi.org/10.1016/j.vaccine.2015.07.039